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Abstract
Background/Aim. Selective serotonin reuptake inhibitors
are the most commonly chosen antidepressants in patients
with Parkinson's disease (PD). The aim of our study was to
assess the influence of fluoxetine (Flu) on motor functions in
patients with PD. Methods. In this prospective, controlled,
open-label study, 18 patients with PD and mild depression
[(10  Hamilton Rating Scale for Depression (HDRS)  23)]
without dementia [(25  Mini-Mental State Examination
(MMSE)] were treated with Flu. Both single and repeated
dose effects of Flu were assessed on days 1–80. Plasma con-
centrations of Flu and norfluoxetine (NORFlu) were corre-
lated with the results of selected motor function performance
scores: The Unified Parkinsons Disease Rating Score
(UPDRS), Finger Tapping Test (FTT) and Purdue Pegboard
Test (PPT). Severity of PD, depression and dementia were
evaluated using standard tests [(Hoehn and Yahr stages (HY),
activity of daily living (ADL), UPDRS, HDRS, MMSE)]. Re-
sults. Steady-state for Flu/NORFlu was reached after 18
days of treatment. Such a plateau correlated with significant
improvements in both scores of depression and Parkinson's
disability (HDRS, UPDRS and ADL, respectively). In addi-
tion, FTT and PPT scores also increased until day 18, with
further slight fluctuations around the plateau. Optimal motor
performances correlated with Flu concentrations of approxi-
mately 60–110 Ƭg/L. Conclusion. Flu (20 mg/day) signifi-
cantly reduced depression in PD patients while it did not im-
pair their motor performances. Because substantial placebo
effects may arise in studies of PD and depression, large, pro-
spective, randomized, placebo-controlled clinical trials are
warranted.
Key words:
parkinson disease; motor activity; depressive disorder;
fluoxetine; treatment outcome.
Apstrakt
Uvod/Cilj. Selektivni inhibitori ponovnog preuzimanja se-
rotonina su antidepresivi koji se najÿešýe koriste u  leÿenju
obolelih od Parkinsonove bolesti (PB). Cilj ovog istraživanja
bio je da se proceni uticaj fluoksetina (Flu)  na motorne
funkcije bolesnika sa PB. Metode. U ovom prospektivnom,
kontrolisanom, otvorenom kliniÿkom ispitivanju, 18 boles-
nika sa PB i blagom depresijom [10  Hamiltonova skala za
depresiju (10  HDRS)  23)], bez demencije [(25  Mini
mental test (MMSE)] leÿeni su primenom Flu. Procenjivana
su dejstva kako pojedinaÿne, tako i ponovljene doze Flu od
prvog do osamdesetog dana. Plazma koncentracije Flu i
norfluoksetina (NORFlu) korelisane su sa rezultatima ode-
Āenih testova za motorne  funkcije: skala za procenu težine
PB (UPDRS), test spretnosti kucanja (FTT) i Purdue peg-
board Test PPT). Izraženost PD, depresije i demencije pro-
cenjivane su korišýenjem standardnih testova [(test dnevnih
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aktivnosti (ADL), Hoehn.-Yahr. stadijumi (HJ), HDRS,
MMSE)]. Rezultati. Ravnotežno stanje za Flu/NORFlu
postignuto je 18. dana leÿenja. Takav plato u koncentraciji
Flu/NORFlu bio je praýen znaÿajnim poboljšanjem rezul-
tata, kako testova za depresiju, tako i za izraženost PB
(HDRS, UPDRS i ADL, sledstveno). Dodatno, rezultati
FTT-a i PPT-a  bili su u porastu do 18. dana, sa blagim flu-
ktuacijama oko platoa. Optimalna motorna postignuýa za-
beležena su pri koncentraciji Flu od oko 60–110 Ƭg/L. Zak-
ljuÿak. Flu (20 mg/dan) znaÿajno redukuje depresiju kod
bolesnika sa PB i ne remeti motorne funkcije. S obzirom na
moguýi placebo efekat u istraživanjima sa PB i depresijom,
neophodna su obimnija, prospektivna, randomizovana, pla-
cebo-kontrolisana kliniÿka ispitivanja.
Kljuÿne reÿi:
parkinsonova bolest; motorna aktivnost; depresioni
poremeýaji; fluoksetin; leÿenje, ishod.
Introduction
Depression is the most common and frequently dis-
abling psychiatric condition in patients with Parkinson's dis-
ease (PD). Prevalence of depression in patients with PD var-
ies from 7% to 76% depending on the assessment method 1.
Such a depression is mostly persistent or recurrent. It may be
accompanied with anxiety, cognitive impairment and may
reduce effectiveness of antiparkinson’s therapy 2–5. Depres-
sion increases PD patients' disability and significantly re-
duces their quality of life. Consequently, approximately 50%
of patients with PD receive antidepressant therapy 4–7.
Optimal treatment for depression in PD patients has not
been established. Several antidepressants were tested in ran-
domized clinical trials without sufficient statistical power
(e.g. citalopram, sertraline, fluoxetine, amitriptyline and
nortriptyline). Amitriptyline seems to be more effective than
fluoxetine in PD patients with severe depression. However, it
is not necessarily the first choice for treatment of depression
in PD patients, according to the recommendations of the
American Academy of Neurology 8. In addition, the adverse
effects of amitriptyline such as orthostatic hypotension, se-
dation, cognitive and anticholinergic effects might preclude
its use and increase the dropout rate in parkinsonians 1, 9, 10.
On the other hand, selective serotonin reuptake inhibi-
tors (SSRIs) are used as a first line treatment of depression
51% of the time 1, 9, 10. In postmortem studies of patients with
PD  depletion of 5-hydroxytryptamine (5-HT) in the caudate
as well as hypothalamus and frontal cortex was reported 11–14,
with preferential loss of 5-HT in the caudate compared with
the putamen, but with relatively less loss of 5-HT (66%) than
dopamine (98%) 15. Imaging studies in vivo have also sug-
gested depletion of 5-HT innervation to the striatum as
measured via decreased 5-HT transporter binding 16–18. The
loss of striatal 5-HT in PD may be secondary to neurodegen-
eration within the raphe nuclei as Lewy bodies are seen in
the raphe nuclei 19, 20, associated with cell loss 21, 22.  Tauscher
et al. 23, 1999, were the first to demonstrate the pharmacody-
namic action of the selective 5-HT transporter blocker
fluoxetine in the human brain in vivo. Meyer et al. 24, 2004,
showed that 80% 5-HT transporter occupancy was achiev-
able with SSRI at therapeutic doses in a study on patients
with mood and anxiety disorders. Apart from these drug-
effects studies, it has been shown that recovery of central se-
rotonergic system after SSRI therapy was associated with re-
duction of clinical symptoms in 18 depressive subjects using
[123|]-CIT and SPECT 25. All these findings of SSRIs-5-HT
transporter occupancy in PET/SPECT studies clearly reflect
the pharmacologically induced changes in serotonergic
transmission 5, 26.
However, data on the efficacy and safety of SSRIs in
PD are still lacking and sufficiently large scale randomised
controlled trials are required. Although the introduction of
SSRIs offers new opportunities for the treatment of depres-
sion in PD, these agents could produce extrapyramidal ad-
verse reactions aggravating parkinsonism 1, 10. While epide-
miological studies have not suggested increased risk of
worsening PD using SSRIs for depression 27, almost one
hundred detailed reports on extrapyramidal adverse effects
linked to  SSRIs  antidepressants have been published 28, 29.
The influence of Flu on motor performances in PD pa-
tients still remains to be clarified. Extrapiramidal side effects
of Flu seem to be related to the exacerbation of Parkinson’s
disability 30. However, it was also reported that Flu did not
increase Parkinson’s disability either in retrospective 31 or in
prospective studies 32. Therefore, the authors argue for more
systemic and controlled research examining the treatment of
depression in patients with PD 1, 33, 34.
The aim of this study was to determine motor perform-
ances of PD patients treated with antidepressant Flu and to
assess a possible correlation between mood and motor per-
formance scores with plasma concentrations of Flu and its
active metabolite, norfluoxetine (NORFlu).
Methods
Efficacy and tolerability of Flu was assessed in the pro-
spective, 80-day, controlled, open-label clinical trial, with
blind assessment. Flu was administered to 18 patients with
nonfluctuating PD in the early Hoehn and Yahr (HY) stages
– as indicator of PD staging only), I and II 35, 36, accompanied
with mild depression [(Hamilton Rating Scale for Depression
(HDRS): 10  HDRS  23)], without dementia [(Mini Men-
tal State Examination (MMSE): t 25)].  These 18 patients
were either de novo PD patients (PD0 group, N = 9), or PD
patients who were on the stable antiparkinsonian treatment
(PDt group, N = 9), without selegiline, rasagiline and/or do-
pamine agonists for at least two months prior to Flu.
Patients with secondary parkinsonism, those with the
MMSE score  25 36, history of stroke, neurological disorder
other than PD, or any concomitant serious medical illness,
and drug toxicity causing hallucinations, confusional epi-
sodes or delirium, were not included in the study. During the
study, patients were not allowed to use neuroleptics, seda-
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tives, hypnotics or other antidepressants, as well as drugs
with potential extrapyramidal adverse effects.
The study was approved by the Ethical Committee of the
Faculty of Medicine, University of Belgrade, Serbia. Before
entering the study patients gave written informed consent.
All the tests were performed in 18 out of 18 patients on
days 11 and 18. Afterwards,  9 out of 18 patients were tested
on day 50, and 8 out of 18 patients on day 80 (dropout rates
of 50% and 56%, respectively). Therefore results were
showed only until day 50.
All the patients were treated with two consecutive dos-
ing regimens.
First, acute treatment with Flu – first day, the patients
received Flu, 20 mg per day, at 8 a.m. Evaluation of motor
performances and blood sampling for Flu/NORFlu plasma
concentration measurement were carried out immediately be-
fore the Flu treatment (day 1, 0 h), and 4 h, 6 h and 8 h after
the administration of the drug. Flu was than withdrawn for
three consecutive days. On the fifth day, patients received 40
mg of Flu at 8 a.m. and all the tests and blood sampling were
repeated in the same order (day 5, 0–8 h after administration
of the drug). The pattern of blood sampling depends on Tmax
for Flu, ranging from 4 to 8 h after the single dose admini-
stration 37 (Figure 1, panel A).
Second, chronic treatment with Flu – in the same pa-
tients, regular Flu treatment was initiated (20 mg per day, at
8 a.m.) on day 6 after the beginning of such a therapy, and
the motor performances were evaluated on days 11, 18, 50
(steady state for Flu was reached after 18 days of Flu treat-
ment) (Figure 1, panel B).
Two blinded refers evaluated severity of motor impair-
ment using the Unified Parkinson's Disease Rating Scale
(UPDRS) – motor score 38, ADL (Schwab and England Ac-
tivities of Daily Living Score) and computerized version of
the quantitative motor test Finger Tapping Test (FTT) 39 and
the Purdue Pegboard Test (PPT) 40. The current severity of
depression was evaluated using the 17-item HDRS 41.
Bioanalytical method used for determination of plasma
Flu and NORFlu concentrations was high performance liquid
chromatography (HPLC) coupled with mass spectrometry
(MS). The method used a liquid chromatograph Therm Sepa-
ration Products Spectra System (Autosampler AS3000,
HPLC binary pump P 2000, Degasser SCM 1000), mass
spectrometer with electro spray ionization source (Finnigan
MAT SSQ 7000 LC/MS – ESI System), Computer Digital
UNIX Alpha Station 255. Recovery was very high, not less
than 90.8% for Flu and 80.2% for NORFlu. Limit of quanti-
fication was 2.5 Pg/L for Flu and 10 Pg/L for NORFlu, and
limit of detection was 1 Pg/L for Flu and 5 Pg/L for NOR-
Flu. Correlation coefficient was 0.9993 (concentration range
of 2.5–250 Pg/L), and 0.9989 (concentration range of 10–
250 Pg/L), for Flu and NORFlu, respectively.  Coefficient of
variation, calculated for precision, was not higher than
8.33% and 8.83% for Flu and NORFlu, respectively.
The results are expressed as the mean ± standard error of
the mean (S.E.M.) of N observations (descriptive statistics).
Comparisons between groups were analyzed using the Fisher's
exact test, t-test, and one-way analysis of variance (ANOVA),
when appropriate. In addition, correlation analysis, factor
analysis, extraction method (principal component analysis),
rotation method (Oblimin with Kaiser normalization) and
trend analysis (fitting or least square method) were used.
Results
All the patients were right-handed. Both groups, PD0
and PDt, had similar laterality of Parkinson’s symptoms (af-
fected right side/affected left side = 6/3).
Among 12/18 patients with the affected right side,
there was no significant difference between FFT for the
right hand (FTTr) and FTT for the left hand (FTTl) scores,
as well as between PPT for the right hand (PPTr) and PPT
for the left hand (PPTl) scores (p = 0.66, and 0.89, respec-
tively).

Flu 20 mg
Day 1 Day 5
Flu 40 mg
8 12 14 16
a.m. a.m. a.m. a.m.
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B
...
Flu 20 mg
Day 11
...
8
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8
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8
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Fig. 1 – Design of the study: acute and chronic treatment of Parkinsonian patients with fluoxetine (Flu)
(panel A – acute treatment with Flu, panel B – chronic treatment with Flu)
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Among 6/18 patients with affected left side, FTTr was
significantly better than FTTl (p = 0.03) and PPTr was sig-
nificantly better than PPTl (p = 0.02). In addition, only PPTr
score was significantly higher in the left side-affected PD
patients comparing to the right side-affected PD patients (p =
0.03).
Age, gender and main clinical scores of PD0- and PDt-
patients are shown in Tables 1 and 2.
Depressive symptoms were similarly reduced after 18
days of Flu treatment in both PD0 and PDt patients (Table 2,
HDRS scores, p < 0.05). At the same time, Parkinson's dis-
ability was remarkably improved, especially in PDt patients
(Table 2, UPDRS and ADL, p < 0.05, both).
Acute treatment with Flu: there were no remarkable
changes in motor function scores (FTT, PPT) after the ad-
ministration of 20 mg of Flu (day 1), or 40 mg of Flu (day 5)
(Table 3).
The groups PD0 and PDt differ only in FTTr scores
at  0 h and 8 h after the administration of 40 mg of Flu
(day 5).
Chronic, treatment with Flu: plasma concentrations of
Flu and NORFlu increased in a time-related manner (CFlu,
and CNORFlu, respectively) (Figure 2).
Table 4 shows plasma concentrations of Flu and NOR-
Flu, as well as motor performance scores for each group as-
sessed during chronic treatment with Flu.
Different patterns of changes were observed in the PD0
and PDt patients. In the former case, a sustained increase in
both CFlu, and CNORFlu was observed until day 18, i.e. the
plateau was reached after 18 days of treatment. In the latter
case, plasma concentrations continuously raised until the end
of the observation period (day 50) (Table 4). CFlu was sig-
nificantly higher in PD0 than in PDt group after 18 days of
treatment (Figure 2A, Table 4).
During chronic treatment with Flu, FTTr scores in the
group PD0 were continuously higher than in the group PDt,
reaching the significance on days 11 and 50 (P = 0.03 and
0.04, respectively) (Table 4). Such a difference was less pro-
nounced regarding FTTl, PPTr and PPTl scores, never
reaching statistical significance.
Table 1
Baseline characteristics of patients with Parkinson’s disease (PD): group of de novo patients without antiparkinson’s
medication (PDo) and the group with previous stable antiparkinson’s therapy (PDt) (mean ± S.E.M.)
Previous levodopa therapyGroup of
patients Age (years)
Duration of PD
(years) Duration(years)
Dose
(mg/day)
MMSE
PD0 (N = 9) 55.7 ± 3.0 2.7 ± 0.9 0 0 28.0 ± 0.6
PDt (N = 9) 56.0 ± 2.7 3.6 ± 1.1 3.9 ± 0.9 458.3 ± 55.1 27.9 ± 0.9
MMSE – mini mental state examination; PD0 – de novo PD patients; PDt  – PD patients with stable antiparkinsons therapy
Table 2
Staging of Parkinson’s disease (PD): the group of patients without antiparkinson’s medication (PD0) and the group of
patients with stable antiparkinson’s therapy (PDt), before (day 1) and on the 18th day of  fluoxetine (Flu) medication (day 18
| steady state for Flu) (mean ± S.E.M.)
HDRS UPDRS ADLGroup of
patients day 1 day 18 day 1 day 18 day 1 day 18
PD0 (N = 9) 16.4 ± 2.1 10.4 ± 1.9 26.7 ± 2.9 23.6 ± 3.4 81.7 ± 3.8 85.0 ± 3.4
PDt (N = 9) 13.6 ± 0.9 8.2 ± 1.1 29.0 ± 5.1 22.2 ± 4.6 82.2 ± 3.3 85.6 ± 3.4
HDRS – Hamilton Depression Motor Scale; UPDRS – Unified Parkinson's Disease Rating Scale; ADL – Schwab and England Activities of Daily
Living Score. – p < 0.05, day 0 vs. day 18 (Student's t-test for paired data).
Table 3
Changes in fluoxetine (Flu) and norfluoxwtine (NORFlu) concentrations, and motor function scores (FTT, PPT) during
acute treatment with Flu (day 1: 20 mg; day 5: 40 mg) (mean ± S.E.M.)җ
Day s of Flu
treatment Day 1 of the treatment Day 5 of the treatment
Parameter Group 0 h 4 h 6 h 8 h 0 h 4 h 6 h 8 h
CFlu  (Pg/L) PD0
PDt
0
0
9.58 r
r
11.44 r
r
14.80 r
r
3.24 r
r
19.98 r
r
23.19 r
r
27.40 r
r
CNORFlu (Pg/L) PD0
PDt
0
0
0
0
0
0
0
0
0
2.57 r
3.57 r
r
7.48 r
r
10.48 r
r
FTTr PD0
PDt
5.11 r
r
4.91 r
r
5.20 r
r
5.01 r
r
5.44 r
r
5.31 r
r
5.19 r
r
5.44 r
r
FTTl PD0
PDt
4.25 r
r
4.34 r
r
4.56 r
r
4.57 r
r
4.42 r
r
4.46 r
r
4.49 r
r
4.83 r
r
PPTr PD0
PDt
10.33r
r
11.56r
r
11.56r
r
11.22r
r
11.33r
r
12.22r
r
11.78r
r
11.89r
r
PPTl PD0
PDt
9.22r
r
9.89r
r
10.67r
r
10.44r
r
10.44r
r
10.67r
r
10.78r
r
10.33r
r
PD – Parkinson’s disease; PD0 – de novo PD patients; PDt – PD patients with stable antiparkinson’s therapy; CFlu, CNORFlu – plasma concentrations of fluoxetine and
norfluoxetine; FTTr, FTTl – Finger Tapping Test for right and left hand; PPTr, PPTl – “Purdue Pegboard Test for right (r) and left (l) hand; * – p < 0.05, PD0 vs. PDt.
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Fig. 2 – Changes in plasma concentrations of fluoxetine
(CFlu) and its active metabolite norfluoxetine (CNORFlu)
over time (panels A and B, respecively) in PD0 () and
PDt patients (), during chronic treatment with Flu (days
11–50, 20 mg/day). Each point represents the mean r
S.E.M. of plasma concentrations obtained from 9
separate PD0 or PDt patients. *p < 0.05, the PD0 vs. the
group PDt
PD – Parkinson’s disease; PD0 – de novo PD patients; PDt – PD pa-
tients with stable antiparkinson’s therapy
Of note, the raise in CFlu between days 0 and 18 (the
plateau) coincided with the increase in FTT and especially in
PPT scores (Tables 3 and 4).
Factor analysis reveals that influence of Flu/NORFlu
concentrations increased over time (cummulative data from
both PD0 and PDt patients; plasma samples were taken on
days 0, 5, 11, and 18, six hours after Flu administration). The
variance explained by the concentrations of Flu and NORFlu
permanently increased from 13.9% (day 5) to 29.9% (day
11) and 37.6% (day 18) of cumulative variance (values of
89.4%, 84.9% and 91.8%, respectively). At the same time,
influence of motor function scores decreased over time: vari-
ance explained by PPT and FTT scores of 75.5%, 55%, and
54.1% (days 5, 11, and 18, respectively).
PPT and FTT scores significantly correlated on day 11 (r
= 0.62; p < 0.01). In addition, an inverse correlation was found
between Flu/NORFlu concentrations and PPT-, but not with
FTT scores, on day 18 (r = -0.70 and 0.48, respectively).
Gastrointestinal, cardiovascular side effects and/or in-
somnia, somnolence and excessive daytime sleepness as ad-
verse reactions to Flu were not reported in the PD patients
considered in the study.
Discussion
The major results of our pilot study show that Flu
treatment may alleviate depression in PD patients without
deterioration of motor function scores.  FTT, PPT and
UPDRS-motor scores were even improved despite the par-
allel increase in plasma concentrations of Flu/NORFlu dur-
ing the first 18 days of the study.
Depression in PD must be properly diagnosed and
treated 42.  However, rare reports on the use of various anti-
depressants in PD patients offer controversial data on their
safety regarding motor adverse reactions. Controlled clinical
studies confirming the efficacy of Flu in PD patiens and as-
sessing the risk-benefit ratio of such a therapy are still lack-
ing 43.
The broad therapeutic window for Flu is due to its
highly variable pharmacokinetics 5, 44–46. Flu steady state is
achieved approximately after 3 weeks (concentrations of ap-
proximately 110 Pg/L). If plasma concentrations increase
above 110 Pg/L, the dosage should be adjusted accordingly.
Factor analyses indicates that mean Flu concentrations of ap-
proximately 60–110 Pg/L have the most powerful effect on
both PPT and FTT scores, which were significantly im-
proved within that concentration range.
Table 4
Changes in fluoxetine (Flu) and norfluoxetine (NORFlu) concentrations, and motor function scores (FTT, PPT)
 during chronic treatment with Flu (days 11–80: 20 mg/day) (mean rS.E.M)
Days of Flu treatmentParameter Group Day 11 Day 18 Day 50
CFlu (Pg/L) PD0PDt
60.73 r
51.97 r
r
r
87.99 r
r
CNorFlu (Pg/L) PD0PDt
62.17 r
60.80 r
129.17 r
82.84 r
106.51 r
181.74 r
FTTr PD0PDt
5.51 r
r
5.56 r
r
5.34 r
r
FTTl PD0PDt
4.62 r
r
4.71 r
r
4.78 r
r
PPTr PD0PDt
12.22r
r
12.89r
r
14.17r
r
PPTl PD0PDt
10.89r
r
11.44r
r
11.81 r
r
PD – Parkinson’s disease; PD0 – de novo PD patients; PDt – PD patients with stable antiparkinson’s therapy; CFlu, CNORFlu –
plasma concentrations of fluoxetine and norfluoxetine; FTTr, FTTl – finger tapping test for right and left hand; PPTr, PPTl –
“Purdue Pegboard Test for right (r) and left (l) hand; * – p < 0.05, PD0 vs. PDt
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The PPT and FTT are quantitative motor tests. While
FTT more reflects motor speed, the PPT is a test for fine
motor functions and coordination 40, 47. Since all the patients
were right-handed only among 6/18 patients with affected
left side FTTr and PPTr were better than FTTl and PPTl, re-
spectively, pointing to more efficient compensatory mecha-
nisms in dominant hand 48, 49.
The pharmacological profile of fluoxetine is unique
among the antidepressants used in PD patients. Fluoxetine is
both SSRI agent and a 5HT2C antagonist 50. A recent investi-
gation confirmed that 5HT1A agonists and 5HT2C antagonists
could be important features in treatment of PD. In particular,
5HT2c receptors seem to tonically inhibit dopamine release
from all three major dopaminergic pathways. Accordingly,
5HT2c antagonists could block such an inhibiton, especially
in the terminal regions of the nigrostriatal and mesolimbic
pathways 51.
Additionally, 5-HT2c receptors are selectively located
within substantia nigra pars reticulata (SNr) and  medial glo-
bus pallidus (GPm) and 5-HT via 5-HT2c receptors is exci-
tatory in the SNr 52–55, which may  contribute to the increased
activity of these regions in PD. Systemic administration of
selective 5-HT2c antagonists to 6-hydroxydopamine-lesioned
rodents potentates the antiparkinsonian action of dopamine
D1 and D2 agonists 56, 57, which is an action mediated via 5-
HT2c receptors in the SNr 56. Thus, 5-HT2c receptor antago-
nists may improve parkinsonism and drugs with 5-HT2c re-
ceptor antagonist action, such as fluoxetine, are unlikely to
worsen PD 57.
 The pathophysiological mechanisms involved in mood
disturbances in PD remain complex. Serotonergic dysfunc-
tion has been postulated as such systems are involved in
mood disorders in non-PD and the raphe nuclei, as well as
hippocampus and prefrontal cortex, appear to be the primary
sites affected 58, 59. Moreover, transcranial ultrasound studies
have suggested an association with reduced brainstem raphe
echogenicity and nigral hyperechogenicity in patients with
depression preceding PD onset compared with nondepressed
patients with PD 60. As the PD disease progresses, Lewy
bodies occur with the rostral raphe, thalamus and limbic and
cortical regions 15–22, 61, which may result in the mediating of
mood disturbances in PD 23–26.
In depression associated with PD, PD-specific pathol-
ogy, with multiple transmitter deficiencies in mesocortical
monoaminergic systems, plays a major role. This includes
the mesocorticolimbic dopaminergic projection as well as
mesocortical noradrenergic and serotonergic projections.
Corticolimbic noradrenergic denervation through cell loss in
the locus coeruleus and serotonergic deneravtion via sero-
tonergic cell loss in the raphe nucleus are also likely to be
important 11–15, 22–26, 62. Postmortem evidence showed lower
density of neurons in the dorsal raphe nuclei in depressed
versus nondepressed patients with PD 22 and cerebro-spinal
fluid measurement in vivo showed reduced serotonin me-
tabolite (5-HIAA) levels in depressed patients with PD 63, 64.
A  [11C]-DASB  PET  study in seven patients with PD with
untreated depression showed elevated serotonin transporter
binding in the prefrontal cortex compared with non-PD-
matched controls 65. Recently, Politis et al. 66 have reported
that the patients with PD with the highest scores for depres-
sive symptoms showed significantly increased [11C]-DSAB
binding in the amigdala, hypothalamus, caudal raphe nuclei
and posterior cingytlate cortex compared with those patients
with low depression scores, though not compared with
healthy controls. The [11C]-DSAB binding values in other
regions, including the anterior cingulate cortex, caudate, in-
sula, prefrontal cortex, putamen rostral raphe nuclei, thala-
mus and ventral striatum, were similarly decreased in pa-
tients with PD, irrespective of their depressive symptoms
scores, compared with the healthy controls. This study dem-
onstrates that depressive symptoms in antidepressant-naïve
patients with PD are associated with relatively higher seroto-
nin binding in raphe nuclei and limbic structures. A relative
increase in serotonin transporter binding in these regions
could reflect either lower extracellular serotonin levels or a
disease-related loss of presinaptic serotonergic neurotrans-
mission in contributing to the pathophysiology of PD depres-
sion 62, 66.
The phenomenology of depression in PD is also differ-
ent from that in patints with non-PD with less anhedonia and
feeling of guilt 67. While etiology of depression in Parkin-
son's disease is unclear (biochemical changes, psychosocial
factors and situational stressors have all been implicated), it
has an adverse effect on the quality of patients' lives and
doctors should ensure that it is diagnosed and properly
treated 1, 4, 5, 68.
Therefore, along with improvement on parkinsonian
quality of life due to antidepressant activity of SSRI,  symp-
toms such as bradikinesia, hypomima, hypophonia that
overlap between depression  and parkinsonism could amelio-
rate because an improvement of mood symptoms 1, 9, 10.
Evenmore, Suzuki et al 69, 2010, suggested that SSRIs such
as fluoxetine potentially are therapeutic drugs for non-motor
symptoms as well as motor symptoms in patients with PD,
since fluoxetine can reverse the downregulation of cell pro-
liferation in the subgranular zone by the unilateral 6-
hydroxydopamine lesion.
All these various mechanisms could explain why the
improvement in Parkinson's disability scores in our patients
coincided with an increase in plasma Flu and NORFlu con-
centrations during the first 18 days of antidepressive treat-
ment.
Another question is to assess the possible difference
between PD0 and PDt patients' response to Flu treatment. The
beneficial effects of Flu on motor symptoms of PD patients
seem to be more pronounced in PDt group (UPDRS and
ADL scores). In addition, PPT scores were mostly higher in
PDt patients during chronic treatment with Flu increasing
continuously by the end of the study (day 50). However, the
antidepressive efficacy of Flu was similar in both PD groups
(HDRS). Also, the statistical significance was rarely ob-
served between those groups regarding motor function
scores; FTT values were even somewhat higher in PD0 pa-
tients on days 11 and 50.
According to Taylor et al. 70, depressive symptoms pre-
cede those of motor dysfunction in 12–37% of patients with
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PD. On the other hand, algorithms for treating depression in
PD suggest that optimal antiparkinsonian treatment should
precede administration of antidepressants 1, 71. Our results
support such an approach only partially: PD0 and PDt groups
did not differ in their response to antidepressive therapy,
while the influence of Flu on motor functions scores was not
consistently related to the pretreatment with antiparkinsonian
drugs. Nevertheless, successfull treatment of PD before the
administration of antidepressants may diminish overlapping
of depressive symptoms and core Parkinson's diasease
symptoms 1.
In the present study, we failed to observe any deteriora-
tion in motor performance scores of patients with PD that
was related to the increase in plasma Flu and NORFlu con-
centrations. A slight improvement was even observed in all
the scores (UPDRS, ADL, FTT and PPT). Similar results
were obtained with citalopram, which improved mood but
did not decrease motor performance scores in PD treated
with levodopa; at the same time, citalopram improved the
parkinsonian dysability, bradykinesia and finger taps after
one and four months of treatment, both in patients with and
without depression 72, 73. Also, Weintraub et al. 44, 2006, re-
ported that escitalopram was well tolerated, but produced
only a partial response in the treatment of major depression
in elderly PD patients (mean age of 72.1 years). Two open-
label studies suggested that sertraline reduced depression in
PD patients, with additional beneficial effect on anxiety,
without influencing motor function 74, 75. Additionaly, Ilic et
al. 76 showed that the treatment with sertraline exerts com-
plex modulatory effects on human motor cortex with poten-
tial behavioural usefulness. In another open-label study with
paroxetine (20 mg/day) given to 33 nondemented depressed
PD patients during 6 months, Ceravolo et al. 77, in 2000, re-
ported a significant improvement of depression, as evaluated
by HDRS, without influence on parkinsonian symptoms. In
only one patient fully reversible worsening of tremor was
observed. However, paroxetine frequently may induce
tremor as an adverse effect, with a prevalence of 1% to 2%.
Chung et al. 78 in 2005, reported that the short-term par-
oxetine treatment did not alter the motor response to levo-
dopa in patients with PD.
On the other hand, in two retrospective studies wors-
ening of motor symptoms was observed in only small num-
ber of PD patients treated with SSRIs 79, 80. In a prospective
study comprising 65 depressed PD out-patients treated with
paroxetine (10–20 mg/day) for at least 3 months, two out of
52 patients who completed the study (3%) experienced wors-
ening of parkinsonian symptoms 79. However, van de Vijver
et al. 80, in 2002, observed that the start of SSRI therapy in
levodopa users was followed by a faster increase of antipar-
kinsonian drug treatment. Gony et al. 81, in 2003, failed to
find any significant difference in the occurrence of serious
extrapyramidal symptoms between different classes of SSRI
antidepressant drugs in patients with PD treated with dopa-
minergic antiparkinsonian drugs. According to the results of
several studies 82–84, including our results with Flu, it seems
that the benefit of SSRIs outweigh the potential problems
due to adverse effects and that they may be considered to be
the rational choice in the treatment of depression in PD.
There are several limitations of the study: it was an
open-label study without randomization including a small
number of patients. As with all nonradomized, open-label
trials at tertiary research centers, many non-specific factors,
such as relatively long duration of symptoms in de novo PD
patients, may have influenced the results. However, the
quantitative evaluations of motor functions using FTT and
PPT significantly improved objectivity and validity of our
findings. The observed dropout rates (50% and 56% on days
50 and 80, respectively) are high but fit to the range observed
in clinical trials to depression 83.
Conclusion
This pilot study suggests that Flu 20 mg is effective and
well tolerated antidepressant in patients with Parkinson’s
disease. In addition, Flu improved motor function scores in
PD patients and such improvement was observed in parallel
with the increase in plasma Flu and NORFlu concentrations.
Also, the effects of Flu were similar in de novo PD patients
and in those already treated with antiparkinsonian medica-
tions.
Therefore, our results would allow an optimal design
for further large, prospective, randomized, placebo-
controlled clinical trials that are necessary to evaluate the ef-
ficacy and safety of SSRI antidepressants and allow the de-
velopment of evidence-based guidelines.
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